México Terapia Celular Mercado Tamaño, Participación, Tendencias y Pronóstico por Tipo de Célula, Tipo de Terapia, Área Terapéutica, Usuario Final y Región, 2026-2034

Overview of the Mexico Cell Therapy Market:

The cell therapy market in Mexico reached USD 269.4 million in 2025. Looking ahead, the IMARC Group expects the market to reach USD 863.2 million by 2034, exhibiting a compound annual growth rate (CAGR) of 13.40% during 2026-2034. Healthcare modernization initiatives, international collaborations, regulatory improvements by COFEPRIS (Federal Commission for Protection against Sanitary Risks), and government incentives for biotechnology companies are the main factors contributing to the market. The expansion of medical tourism, the availability of affordable treatments, improvements in clinical quality, and increased domestic demand for regenerative therapies are other contributing factors. The evolution of the insurance model, the growth of university-driven research, and patient access initiatives are some of the factors positively influencing the cell therapy market share in Mexico.

Trends in the Mexico Cell Therapy Market:

Progress of national health modernization programs

One of the main drivers of the market is the progress of national healthcare modernization initiatives. The Mexican government is investing in improving healthcare infrastructure, with a particular focus on expanding access to specialized medical services, such as regenerative medicine and cell therapies. Through collaboration with international healthcare organizations and private stakeholders, Mexico is facilitating technology transfer and training programs that enhance local expertise. New specialized hospitals and research centers are being established to support the clinical application and commercialization of cell therapies. Improved regulations by agencies such as COFEPRIS are enabling a clearer and more efficient pathway for the approval of innovative therapies, increasing confidence among both investors and the public. Furthermore, government incentives for biotechnology and medical device startups are fostering a more dynamic innovation ecosystem. As a result, these strategic efforts are significantly driving the growth of the cell therapy market in Mexico. Mexico's large and diverse patient population also provides a fertile environment for clinical research and the validation of novel cell therapies. Partnerships with academic institutions are further strengthening Mexico’s position as a hub for regenerative medicine development, supporting the translation of scientific discoveries into patient-ready treatments across a range of therapeutic areas. On October 29, 2024, Terumo Blood and Cell Technologies announced its efforts to advance the automated manufacturing of cell and gene therapies in Latin America, including Brazil, Colombia, and Mexico. The initiative focuses on improving efficiency and reducing costs in the production process, which is crucial for making these therapies more accessible to patients in the region, especially given their reliance on public healthcare systems.

Increase in medical tourism and regional demand for advanced therapies

Another key factor driving the market is the rise in medical tourism, coupled with growing regional demand for cutting-edge therapeutic options. Mexico's geographic proximity to the United States, combined with significantly lower treatment costs, makes it an attractive destination for patients seeking access to advanced cell therapies. Several specialized clinics and hospitals in major cities, such as Tijuana, Guadalajara, and Monterrey, offer innovative regenerative treatments that meet international standards. This influx of international patients is spurring increased investment in clinical quality, regulatory compliance, and technological innovation. Simultaneously, domestic demand for cell therapies is growing as awareness of regenerative medicine options spreads across various socioeconomic groups. Collaborative initiatives between public health authorities and private clinics are expanding patient access to approved regenerative therapies. On September 27, 2024, Johnson & Johnson announced that CARVYKTI® (ciltacabtagene autoleucel) has become the first and only cell therapy to significantly extend overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma, even as a second-line therapy. The Phase 3 CARTITUDE-4 study demonstrated a 45% reduction in the risk of death after three years of follow-up, establishing CARVYKTI® as a transformative treatment for these patients. The evolution of insurance coverage models for specialized treatments is another significant factor facilitating wider adoption. Research and development efforts are also intensifying, with several Mexican universities playing an active role in clinical trials and laboratory innovation. Overall, the combination of cross-border demand for healthcare, lower costs, extensive clinical expertise, and supportive government policies is reinforcing Mexico's emerging position in the global cell therapy landscape.

Segmentation of the Mexico Cell Therapy Market:

IMARC Group offers an analysis of key trends in each market segment, along with national and regional forecasts for 2026-2034. Our report has categorized the market based on cell type, therapy type, therapeutic area, and end user.

Cell Type Insights:

• Stem cells
  • Bone marrow
  • Blood
  • Umbilical cord derivatives
  • Stem cells derived from adipose tissue
  • Others
• Non-stem cell

The report offers a detailed breakdown and analysis of the market based on cell type. It includes stem cells (from bone marrow, blood, umbilical cord, adipose tissue-derived stem cells, and others) and non-stem cells.

Insights tipo de terapia:

• Autólogo
• Alogénico

El informe ofrece un desglose y un análisis detallados del mercado en función del tipo de terapia. Se incluyen las autólogas y las alogénicas.

Insights área terapéutica:

• Malignas
• Trastornos musculoesqueléticos
• Trastornos autoinmunitarios
• Dermatología
• Otros

El informe ofrece un desglose y un análisis detallados del mercado en función del área terapéutica. Se incluyen malignos, trastornos musculoesqueléticos, trastornos autoinmunitarios, dermatología y otros.

Insights de los usuarios finales:

• Hospitales y clínicas
• Institutos académicos y de investigación

El informe ofrece un desglose y un análisis detallados del mercado en función del usuario final. Esto incluye hospitales y clínicas e institutos académicos y de investigación.

Insights regionales:

• Norte de México
• México Central
• Sur de México
• Otros

El informe también ha proporcionado un análisis exhaustivo de los principales mercados regionales, que incluyen el norte de México, el centro de México, el sur de México y otros.

Panorama competitivo:

El informe de investigación de mercado también ha proporcionado un análisis exhaustivo del panorama competitivo. El informe incluye análisis de la competencia como la estructura del mercado, el posicionamiento de los actores clave, las principales estrategias ganadoras, el cuadro de mando de la competencia y el cuadrante de evaluación de las empresas. También se ofrecen perfiles detallados de las principales empresas.

Noticias del México Terapia Celular Mercado:

• El 8 de abril de 2025, Stem Vitality México anunció que está ampliando el acceso a tratamientos asequibles con células madre para pacientes de EE.UU. y Canadá, ofreciendo terapias para una serie de enfermedades, incluyendo dolor crónico, trastornos autoinmunes y problemas ortopédicos. La clínica aprovecha la infraestructura de turismo médico establecida en México para ofrecer asistencia bilingüe, ayuda en el viaje y atención personalizada.

Cobertura del México Terapia Celular Mercado:

Key questions answered in this report:

• How has the cell therapy market performed in Mexico so far, and how will it perform in the coming years?
• What is the breakdown of the cell therapy market in Mexico based on cell type?
• What is the breakdown of the cell therapy market in Mexico by type of therapy?
• How is the cell therapy market in Mexico distributed by therapeutic areas?
• What is the breakdown of the cell therapy market in Mexico based on the end user?
• How is the cell therapy market distributed in Mexico by region?
• What are the different stages of the cell therapy market value chain in Mexico?
• What are the main driving factors and challenges of the cell therapy market in Mexico?
• What is the structure of the cell therapy market in Mexico and who are its main players?
• What is the level of competition in the cell therapy market in Mexico?

Main benefits for stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and market dynamics of cell therapy in Mexico from 2020 to 2034.
• The research report provides the latest information on market drivers, challenges, and opportunities in the cell therapy market in Mexico.
• Porter's Five Forces analysis helps stakeholders assess the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition in the cell therapy sector in Mexico and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of the major market players.